Approved

U.S. Patent and Trademark On Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

SI	ubstitute for form 1	449B/P	'' O'Y'	'		omplete if Known
INF	ORMATION DIS	CLOS	URE	و سر	Filing Date	10/522,130 January 19, 2005
		7	٠	1 2000	First Named Inventor Group Art Unit	Murray Goodman
(USB	as many sheets	es ned	e See of IR	AD BURNEY	Examiner Name Attorney Docket Number	SDUC1100J-1 (041673-3109)

Examiner Initials*  U.S. Patent Document  Name of Patentee or Applicant of Cited Docum			U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
		 Kind	Name of Patentee or Applicant of	Cited Document	Where Relevant Passages or Relevant

				FC	REIGN PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines, Where Relevant	İ
Examiner Initials*	Cite No.1	Fo Office <sup>5</sup>	oreign Patent [	Kind Code <sup>*</sup>	Name of Patentee or Applicant of Cited Documents	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Te
เกเนสเจ				(if known)	Whitehead Institute for	07-11-1991		1
	A1	wo	91/09958		Biomedical Research			+-
	<u> </u>		04/04606		Biogen, Inc.	03-03-1994		1
	A2	wo	94/04686			1000		+
	A3	wo	98/52614		The Board of Trustees of the Leland Stanford Junior University	11-26-1998		_
	↓	↓	<b> </b>				<b> </b>	1

		NON PATENT LITERATURE DOCUMENTS	T				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
	A4	BUSCHLE, M. et al., Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA., 94, p. 3256-3261 (1997).					
	A5	EMI, N. et al., Gene Transfer Mediated by Polyarginine Requires a Formation of Big Carrier-Complex of DNA Aggregate, Biophys. Res. Commun., 231, p. 421-424 (1997).					
·	A6	FEICHTINGER, L. et al., Triurethane-Protected Guanidines and Triflydiurethane-Protected Guanidines: New Reagents for Guanidinylation Reactions, J. Org. Chem., 63, p. 8432 (1998).					
	A7	LEONETTI, JP. et al., Biological Activity of Oligonucleotide-Poly(L-lysine) Conjugates:  Mechanism of Cell Uptake, Bioconjugate Chem., 1, p. 149-153 (1990).					
<del></del>	A8	MITCHELL, D.J. et al., Polyargine enters cells more efficiently than other polycationic homopolymers, J. Peptide Res., 55 p. 318-325 (2000).					
	A9	MURPHY, J.E. et al., A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery, Proc. Natl. Acad. Sci. USA., 95, p. 1517-1522 (1998).					

Examiner	/David Lukton/	Date Considered	02/19/2009
Signature	Little If reference considered, whether or not citation is in conformance with MPEP 60	Draw line through citation i	f not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandra, VA 22313-1459.

considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3 \*For Japanese patent documents, the indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if \*Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if \*Fortish Institute to the standard ST. 16 if possible and the standard ST. 16 if possible are the standard ST. 16 if possi

MODIFIED PTO/SB/08 (08-00)
Approved through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark ON U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control

Complete if Known number. Substitute for form 1449B/PTO INFORMATION DISCLOSURE 10/522,130 **Application Number** January 19, 2005 Filing Date STATEMENT BY APPLICANT Murray Goodman First Named Inventor AUS 1 1 2005 Group Art Unit (use as many sheets as necessary) **Examiner Name** SDUC1100J-1 (041673-3109) Attomey Docket Number PANEMARY of Sheet

		NON PATENT LITERATURE DOCUMENTS	т6					
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	A10	PEPINSKY, R.B. et al., Specific Inhibition of a Human Papillomavirus E2 <i>Trans</i> -Activator by Intracellular Delivery of Its Repressor, DNA Cell Biol., 13, p. 1011-1019 (1994).						
	A11	RYSER, H.JP., A Membrane Effect of Basic Polymers dependent on Molecular Size, Nature (London), 215, p. 934-936 (1967).						
	A12	RYSER, N.JP. et al., Conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methotrexate to poly(L-lysine) increases drug transport and conjugation of methods are conjugation of methods and conjugation of methods are conjugation of methods and conjugation of methods are						
	A13	Delivery of a Biologically Active Protein Transduction: Delivery of a Biologically Active Protein						
	A14	SHEN, W., et al., Conjugation of poly-L-lysine to albumin and horseradish peroxides: A novel method of enhancing the cellular uptake of proteins, Proc. Nat. Acad. Sci. USA., 75, p. 1872-1876 (1978).						
	A15	VOCERO-AKBANI, A.M. et al., Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein, Nat. Med., 5, p. 29-33 (1999).						
	A16	WENDER, P.A. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA., 97, p. 13003-13008 (2000).						

Examiner	/David Lukton/	Date Considered	02/19/2009
Signature	the containing is in conformance with MPEP 605	. Draw line through citation if	not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>4</sup>Applicant is to place a check mark here if English language Translation is attached.